Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease
Takeharu Yamanaka,
Koji Yamamoto,
Yasushi Honda,
Kento Imajo,
Yuji Ogawa,
Takaomi Kessoku,
Takashi Kobayashi,
Anna Ozaki,
Satoru Saito,
Michihiro Iwaki,
Yusuke Saigusa,
Haruki Usuda,
Koichiro Wada
Affiliations
Takeharu Yamanaka
4 Department of Biostatics, Yokohama City University, Yokohama, Japan
Koji Yamamoto
9 General Medicine, Sumitomo Hospital, Osaka, Japan
Yasushi Honda
professor emeritus
Kento Imajo
Department of Gastroenterology, Yokohama City University, Yokohama, Kanagawa, Japan
Yuji Ogawa
Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan
Takaomi Kessoku
Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan
Takashi Kobayashi
Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan
Anna Ozaki
Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan
Satoru Saito
Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan
Michihiro Iwaki
Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Yusuke Saigusa
Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Haruki Usuda
Department of Pharmacology, Shimane University Faculty of Medicine Graduate School of Medicine, Izumo, Shimane, Japan
Koichiro Wada
Department of Pharmacology, Shimane University Faculty of Medicine Graduate School of Medicine, Izumo, Shimane, Japan
